Skip to main content

Table 1 Patient characteristics

From: Liquid biopsy for patients with IBD-associated neoplasia

 

Patient

Neoplasia

Values of biomarkers

Case no.

IBD type

Age (years)

Sex

Extent of disease

Duration (years)

Location

Type

Histology

Stage

Treatment

CEA (ng/mL)

CA19-9 (U/mL)

CRP (mg/dL)

1

CD

42

M

ileocolonic

15

Rectum

5

Muc

3

Surgery

3.7

10.5

7.3

2

CD

70

M

Ileal

20

Ileum

5

Por

2

Surgery

1.9

27.4

0

3

UC

35

M

Pancolitis

26

Ascending

2

Por

2

Surgery

2.7

10.8

0.05

4

UC

62

F

Pancolitis

36

Sigmoid

5

Muc

3

Surgery

3.0

18.2

0.2

5

UC

48

F

Pancolitis

25

Rectum

5

Muc

2

Surgery

1.2

8.8

3.7

6

UC

40

F

Pancolitis

14

Rectum

0-IIb

HGD

–

Surgery

1.7

30.9

0.02

7

UC

49

F

Left-sided

7

Sigmoid

0-IIa + IIb

HGD

–

ESD

1.3

9.4

0.04

8

UC

83

F

Pancolitis

17

Rectum

0-IIa

HGD

–

Surgery

1.5

7.6

0.4

9

UC

53

M

Pancolitis

30

Rectum

0-IIc

Tub1

Tis

Surgery

2.7

8.1

0.05

10

UC

34

F

Left-sided

14

Rectum

0-Ia

Pap

Tis

Surgery

0.2

10.5

0.06

  1. Abbreviation: IBD inflammatory bowel disease, UC Ulcerative colitis, CD Crohn disease, M Male, F Female, I Ileum, A ascending colon, S sigmoid colon, R Rectum, ESD Endoscopic submucosal dissection, tub1 well differentiated tubular adenocarcinoma, tub2 moderately differentiated tubular adenocarcinoma, pap papillary adenocarcinoma, muc mucinous adenocarcinoma, por poorly differentiated adenocarcinoma, HGD high grade dysplasia, Tis carcinoma in situ